Next Article in Journal
Are Patients with Active Cancer and Those with History of Cancer Carrying the Same Risks of Recurrent VTE and Bleeding While on Anticoagulants?
Next Article in Special Issue
Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges
Previous Article in Journal
Emerging Therapeutic Activity of Davallia formosana on Prostate Cancer Cells through Coordinated Blockade of Lipogenesis and Androgen Receptor Expression
Previous Article in Special Issue
Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 12
Issue 4
10.3390/cancers12040916
Review Report
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

The Landscape of Targeted Therapies in TNBC

Cancers 2020, 12(4), 916; https://doi.org/10.3390/cancers12040916
by Elena Vagia *, Devalingam Mahalingam and Massimo Cristofanilli
Reviewer 1: Anonymous
Reviewer 2:
Peter Kern
Cancers 2020, 12(4), 916; https://doi.org/10.3390/cancers12040916
Submission received: 23 February 2020 / Revised: 24 March 2020 / Accepted: 27 March 2020 / Published: 8 April 2020
(This article belongs to the Special Issue Triple-Negative Breast Cancer: Molecular Characteristics, Treatment Challenges and Solutions)

Round 1

Reviewer 1 Report

See Attached.

Comments for author File: Comments.docx

Author Response

Dear Reviewer, 

Thank you very much for your valuable comments. Please see attachment for the detailed responses. 

Sincerely,

Elena Vagia

Author Response File: Author Response.docx

Reviewer 2 Report

Congratulations to this comprehensive overview on the current landscape of TNBC and future directions of research which has been well elaborated on the basis of numerous references of the international literature. This paper clearly merits publication, however a list of typing errors has to be amended beforehand. Where stated, please add the literature recommended.

With kind regards

Typing errors / amendments / additional references - 

The respective lines of the manuscript are indicated: 

17: clonal evolution (Comment: Please quote Nik-Zainal S. et al.; Landscape of somatic mutations in 560 breast cancer whole-genome sequences; Nature 2016 Jun 2;534(7605):47-54. Here it is stated that mutations are acquired at earliest mutational state in TNBC.)

48: compared instead of compare

55: empty spaces

82: in view instead of in viwe

177: development instead of d evelopment

219: no benefit in OS (Comment: Please quote Hahnen E et al.; Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial; JAMA Oncol. 2017 Oct 1;3(10):1378-1385. In this paper it is stated, that the non-BRCA-mutated patients had the most benefit from the addition of Carboplatin.)

235: no benefit by Carboplatin or Bevacizumab (Comment: This applied when no pCR occurred.) 

305: mediated instead of madiated

340 : 27,2 % instead of 27,2

392: slight instead of slide

393: delete empty spaces

475: alpelisib instead of alpelicib

542: eliminate empty spaces

562: empty space is missing

569: endothelial instead of engothelial

581: patients instead of parients

588: numerous instead of noumerous

657: empty space is missing

677: when to deinstead of when

Author Response

Dear Reviewer, 

Thank you very much for your valuable comments. Please see the attachment with respective responses. 

Sincerely,

Elena Vagia

Author Response File: Author Response.docx

Back to TopTop